Quidel Corp (QDEL) Misses Q2 EPS by $1.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
QuidelOrtho Reports Second Quarter 2022 Financial Results
August 4, 2022 4:10 PM EDTHighlights
Revenue of $613.4 million increased by 247% as reported; Supplemental combined revenue of $898.5 million increased by 37.5% in constant currency and 9.0%, excluding COVID-19 revenue Strong growth in all business units, excluding COVID-19 revenue, including double-digit growth in Point-of-Care and Molecular Diagnostics, and high-single-digit combined growth in Labs and Transfusion Medicine Strength across all major regions, including China, EMEA, and North America GAAP EPS of $0.36; Supplemental combined adjusted EPS of $2.12, a 123% increase from prior year, largely reflecting the strength of high margin COVID-19... More